REG - Aptamer Group PLC - Aptamer Group project with consumer goods company

AptamerAnnouncement

30/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230130:nRSd1755Oa&default-theme=true

RNS Number : 1755O  Aptamer Group PLC  30 January 2023

30 January 2023

 

Aptamer Group plc

("Aptamer", or " the Group")

 

Aptamer Group signs follow on project with multi-national consumer goods
company

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, announces that following
initial positive results from a project with a multi-national consumer goods
company, it has signed a follow on deal to develop Optimer binders as novel
solutions for a direct-to-consumer personal care product.

The deal could be worth up to £185,000, subject to the successful progression
of Optimer development, and is the latest in a series of new contracts that
demonstrates strong momentum in the first weeks of the second half of the
year. Today's deal builds on announced work to date including £1.0m in signed
orders and £1.0m of recognised H1 revenue announced in a recent trading
update, as well as £500,000 from two fee-for-service contracts, announced
last week.

Dr Arron Tolley, Chief Executive Officer, commented: "It's been a busy
January at Aptamer, and this latest deal reflects the momentum within the
business and the demand for our aptamer solutions.

 

"We're pleased to continue our work with this multi-national consumer goods
company on this interesting personal care application, further validating our
technology and our leadership position in developing novel aptamers. This deal
also showcases the wider applicability of our technology and that Optimer
binders can support improved solutions within the cosmetic development space.
I look forward to reporting further progress on this highly exciting project."

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
 
     +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy
 
+44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145.0 billion. Optimer binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIGDBBSDDGXC